UPPSALA, SWEDEN, and SALT LAKE CITY (February 3, 2026) – Sweden-based Rarity Bioscience today announced that ARUP Laboratories, a leading

With a growing customer base in North America, Rarity Bioscience has now established a subsidiary, Rarity Bioscience Inc., incorporated in

Rarity Bioscience has received the prestigious Disruptive Technology Award for its proprietary technology, superRCA™, which enables exceptionally sensitive detection of

We are delighted to welcome Dr. Andrea Ballagi to the board of Rarity Bioscience.  Dr. Ballagi brings extensive expertise in

We are proud to announce that Rarity Bioscience is partnering with Beckman Coulter Life Sciences – a collaboration that will

Rarity Bioscience is thrilled to announce the release of its pioneering superRCA NPM1 Mutation Kit RUO™ and its universal Accessory

Nick brings over 40 years of leadership in the life sciences tools and diagnostics industry, having shaped the strategic direction

We are excited to announce that Rarity Bioscience is a Gold Sponsor at the upcoming ESCCA 2024 Conference, reaffirming our commitment to advancing scientific cell analysis. The European Society for Clinical Cell Analysis (ESCCA) Conference is a leading event that unites top experts and researchers worldwide to discuss cutting-edge developments in flow cytometry and related technologies.

Mr. Joe Bernardo joins Rarity Bioscience as a private investor in a recent funding round. Additionally, he will take on the role of Strategic Business Advisor to the board, with a primary focus on commercialization, partnerships, and expanding into the US market.

Rarity Bioscience is pleased to announce the successful closure of a €6.5 million funding round. This latest round of investment was led by Navigare Ventures, with strong support from existing shareholders, including Novalis Biotech and UU Invest, as well as external strategic investors.

Rarity Bioscience is proud to announce that the esteemed Professor Carl-Henrik Heldin has joined its Scientific Advisory Board as an

Rarity Bioscience’s Linus Bosaeus and Lei Chen was at the CYTO 2024 Conference in Edinburgh, to present the study Ultra-sensitive Molecular MRD on Flow Cytometer using superRCA Mutation Assay, showcasing our new ultra-sensitive mutation detection technology superRCA.

Rarity Bioscience was at the Nordic Precision Medicine Forum, presenting an engaging study that highlights the latest advancements in precision oncology: “Ultra-sensitive Monitoring of Minimal Residual Disease (MRD) for Cancer Patients, using superRCA Mutation Assays with Flow Cytometry Readout”

Amidst the vibrant ambiance of Uppsala Science Park, on the evening of April 10th, a gathering of over a hundred

Download the poster here! Rarity Bioscience proudly engaged in the Biomarkers Congress 2024, presenting the poster ”Non-invasive patient stratification and treatment follow-up using ctDNA in colorectal cancer patients”

Rarity Bioscience will be at the ESH 4th How to Diagnose and Treat Acute Leukaemias Conference to present the poster

Explore our profile here! Let’s make collaboration seamless! We are excited to announce that Rarity Bioscience is now a Registered Supplier on Scientist.com

Download the presentation here Linus Bosaeus, CEO at Rarity Bioscience, entered the ASH Annual Meeting 2023 for an interesting conference,